{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:27:04Z","timestamp":1764350824899,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004305","name":"Shahroud University of Medical Sciences","doi-asserted-by":"publisher","award":["99135"],"award-info":[{"award-number":["99135"]}],"id":[{"id":"10.13039\/501100004305","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vice-chancellery for research and technology at Iranian Ministry of Health and Medical Education","award":["2302"],"award-info":[{"award-number":["2302"]}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["2021\/1169483-0","2022\/1217943-1"],"award-info":[{"award-number":["2021\/1169483-0","2022\/1217943-1"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to evaluate the reactogenicity effects of COVID-19 vaccines, used in Iran.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>At least 1000 people were followed up with phone calls or self-report in a mobile application within 7\u00a0days after vaccination. Local and systemic reactogenicities were reported overall and by subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The presence of one or more local and systemic adverse effects after the first dose of vaccines was 58.9% [(95% Confidence Intervals): 57.5\u201360.3)] and 60.5% (59.1\u201361.9), respectively. These rates were reduced to 53.8% (51.2\u201355.0) and 50.8% (48.8\u201352.7) for the second dose. The most common local adverse effect reported for all vaccines was pain in the injection site. During the first week after the first dose of vaccines, the frequency of the pain for Sinopharm, AZD1222, Sputnik V, and Barekat was 35.5%, 86.0%, 77.6%, and 30.9%, respectively. The same rates after the second dose were 27.3%, 66.5%, 63.9%, and 49.0%. The most common systemic adverse effect was fatigue. In the first dose, it was 30.3% for Sinopharm, 67.4% for AZD1222, 47.6% for Sputnik V, and 17.1% for Barekat. These rates were reduced to 24.6%, 37.1%, 36.5%, and 19.5%, in the second dose of vaccines. AZD1222 had the highest local and systemic adverse effects rates. The odds ratio of local adverse effects of the AZD1222 vaccine compared to the Sinopharm vaccine were 8.73 (95% CI 6.93\u201310.99) in the first dose and 4.14 (95% CI 3.32\u20135.17) in the second dose. Barekat and Sinopharm had the lowest frequency of local and systemic adverse effects. Compared to Sinopharm, systemic adverse effects were lower after the first dose of Barekat (OR\u2009=\u20090.56; 95% CI 0.46\u20130.67). Reactogenicity events were higher in women and younger people. Prior COVID-19 infection increased the odds of adverse effects only after the first dose of vaccines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pain and fatigue were the most common reactogenicities of COVID-19 vaccination. Reactogenicities were less common after the second dose of the vaccines. The adverse effects of AZD1222 were greater than those of other vaccines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08103-4","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:21:49Z","timestamp":1679862109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system"],"prefix":"10.1186","volume":"23","author":[{"given":"Mostafa","family":"Enayatrad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roqayeh","family":"Aliyari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajad","family":"Sahab-Negah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sairan","family":"Nili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Fereidouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvin","family":"Mangolian Shahrbabaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ansari-Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abtin","family":"Heidarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba","family":"Shahraki-Sanavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansooreh","family":"Fateh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Khajeha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Emamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elahe","family":"Behmanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Sheibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Abbaszadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Valikhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Binesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Vahedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Chaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-1105","authenticated-orcid":false,"given":"Mohammad Hassan","family":"Emamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"issue":"27","key":"8103_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"10247","key":"8103_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","volume":"396","author":"S Stringhini","year":"2020","unstructured":"Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313\u20139.","journal-title":"Lancet"},{"key":"8103_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","volume":"28","author":"G Forni","year":"2021","unstructured":"Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28:626\u201339.","journal-title":"Cell Death Differ"},{"key":"8103_CR4","unstructured":"World Health Organization. Draft landscape of COVID-19 candidate vaccines 2023. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed 8 Jan 2023."},{"key":"8103_CR5","unstructured":"World Health Organization. Coronavirus disease (COVID-19): vaccines. 2022. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/coronavirus-disease-(covid-19)-vaccines. Accessed 8 Jan 2023."},{"issue":"25","key":"8103_CR6","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427\u201338.","journal-title":"N Engl J Med"},{"issue":"10275","key":"8103_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"D Logunov","year":"2021","unstructured":"Logunov D, Dolzhikova I, Shcheblyakov D, Tukhvatulin A, Zubkova O, Dzharullaeva A. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671\u201381.","journal-title":"Lancet"},{"issue":"7","key":"8103_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939\u201349.","journal-title":"Lancet Infect Dis"},{"key":"8103_CR9","unstructured":"Centre for Disease Control Prevention (CDC). Possible Side Effects After Getting a COVID-19. Updated Sept. 14, 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after.html. Accessed 23 Feb 2023."},{"issue":"8","key":"8103_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring\u2014United States, December 14, 2020\u2013January 13, 2021. Morb Mortal Wkly Rep. 2021;70(8):283.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"7830","key":"8103_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589\u201393.","journal-title":"Nature"},{"issue":"25","key":"8103_CR12","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439\u201350.","journal-title":"N Engl J Med"},{"key":"8103_CR13","unstructured":"World Health Organization. Protocol template to be used as template for observational study protocols: sentinel surveillance of adverse events of special interest (AESIs) after vaccination with COVID-19 vaccines, 2021. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/342194\/9789240029507-eng.pdf?sequence=1."},{"issue":"1","key":"8103_CR14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1186\/s12889-022-13575-1","volume":"22","author":"R Aliyari","year":"2022","unstructured":"Aliyari R, Mahdavi S, Enayatrad M, Sahab-Negah S, Nili S, Fereidooni M, et al. Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran. BMC Public Health. 2022;22(1):1153.","journal-title":"BMC Public Health"},{"issue":"1","key":"8103_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12879-022-07284-8","volume":"22","author":"I Nachtigall","year":"2022","unstructured":"Nachtigall I, Bonsignore M, Hohenstein S, Bollmann A, G\u00fcnther R, Kodde C, et al. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers. BMC Infect Dis. 2022;22(1):291.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"8103_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40264-022-01151-w","volume":"45","author":"A Kant","year":"2022","unstructured":"Kant A, Jansen J, van Balveren L, van Hunsel F. Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands. Drug Saf. 2022;45(4):319\u201331.","journal-title":"Drug Saf"},{"issue":"1","key":"8103_CR17","doi-asserted-by":"publisher","first-page":"21464","DOI":"10.1038\/s41598-021-00963-7","volume":"11","author":"F Babamahmoodi","year":"2021","unstructured":"Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise G, et al. Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci Rep. 2021;11(1):21464.","journal-title":"Sci Rep"},{"issue":"12","key":"8103_CR18","first-page":"4418","volume":"25","author":"S Andrzejczak-Grz\u0105dko","year":"2021","unstructured":"Andrzejczak-Grz\u0105dko S, Czudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. 2021;25(12):4418\u201321.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"8103_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jiac.2021.09.009","volume":"28","author":"M Saita","year":"2022","unstructured":"Saita M, Yan Y, Ito K, Sasano H, Seyama K, Naito T. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers in Japan. J Infect Chemother. 2022;28(1):116\u20139.","journal-title":"J Infect Chemother"},{"issue":"7","key":"8103_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac314","volume":"9","author":"AI Scher","year":"2022","unstructured":"Scher AI, Berjohn CM, Byrne C, Colombo RE, Colomba CJ, Edwards MS, et al. An analysis of SARS-CoV-2 vaccine reactogenicity: variation by type, dose, and history, severity, and recency of prior SARS-CoV-2 infection. Open Forum Infect Dis. 2022;9(7): ofac314.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"8103_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","volume":"21","author":"N Sutton","year":"2022","unstructured":"Sutton N, San Francisco Ramos A, Beales E, Smith D, Ikram S, Galiza E, et al. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. Expert Rev Vaccines. 2022;21(9):1301\u201318.","journal-title":"Expert Rev Vaccines"},{"key":"8103_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.876336","volume":"10","author":"S Ganesan","year":"2022","unstructured":"Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE. An observational study. Front Public Health. 2022;10: 876336.","journal-title":"Front Public Health"},{"issue":"10","key":"8103_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.vaccine.2022.01.062","volume":"40","author":"FTT Lai","year":"2022","unstructured":"Lai FTT, Leung MTY, Chan EWW, Huang L, Lau LKW, Peng K, et al. Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): a prospective cohort study with intensive monitoring. Vaccine. 2022;40(10):1390\u20136.","journal-title":"Vaccine"},{"issue":"12","key":"8103_CR24","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/jcm10122629","volume":"10","author":"A Riad","year":"2021","unstructured":"Riad A, Sa\u011f\u0131ro\u011flu D, \u00dcst\u00fcn B, Pokorn\u00e1 A, Klugarov\u00e1 J, Attia S, et al. Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey. J Clin Med. 2021;10(12):2629.","journal-title":"J Clin Med"},{"key":"8103_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijid.2021.07.052","volume":"110","author":"S Al Bahrani","year":"2021","unstructured":"Al Bahrani S, Albarrak A, Alghamdi OA, Alghamdi MA, Hakami FH, Al Abaadi AK, et al. Safety and reactogenicity of the ChAdOx1 (AZD1222) COVID-19 vaccine in Saudi Arabia. Int J Infect Dis. 2021;110:359\u201362.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"8103_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.therap.2021.07.004","volume":"77","author":"L Chouchana","year":"2021","unstructured":"Chouchana L, Canou\u00ef E, Batista R, Contejean A, Cariou A, Treluyer JM, et al. Balancing the reactogenicity of the ChAdOx1 nCov-19 vaccine against SARS-CoV-2 and the urgent need of a large immunization in healthcare workers. Therapie. 2021;77(3):371.","journal-title":"Therapie"},{"key":"8103_CR27","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/IJGM.S310497","volume":"14","author":"NA El-Shitany","year":"2021","unstructured":"El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study. Int J Gen Med. 2021;14:1389.","journal-title":"Int J Gen Med"},{"issue":"6","key":"8103_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/vaccines9060556","volume":"9","author":"MM Hatmal","year":"2021","unstructured":"Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines (Basel). 2021;9(6):556.","journal-title":"Vaccines (Basel)"},{"key":"8103_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.08.21251366","author":"R Jayadevan","year":"2021","unstructured":"Jayadevan R, Shenoy R, Anithadevi T. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.02.08.21251366.","journal-title":"medRxiv"},{"key":"8103_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.794642","volume":"12","author":"WH Mahallawi","year":"2021","unstructured":"Mahallawi WH, Mumena WA. Reactogenicity and immunogenicity of the Pfizer and AstraZeneca COVID-19 vaccines. Front Immunol. 2021;12: 794642.","journal-title":"Front Immunol"},{"key":"8103_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijid.2021.08.013","volume":"111","author":"BQ Saeed","year":"2021","unstructured":"Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219\u201326.","journal-title":"Int J Infect Dis"},{"issue":"10267","key":"8103_CR32","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2021;396(10267):1979\u201393.","journal-title":"Lancet"},{"issue":"19","key":"8103_CR33","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1\u20132a trial of Ad26. COV2. S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"8103_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","volume":"6","author":"I McDonald","year":"2021","unstructured":"McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6(1):74.","journal-title":"NPJ Vaccines"},{"issue":"5","key":"8103_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102207","volume":"15","author":"HB Almufty","year":"2021","unstructured":"Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021;15(5): 102207.","journal-title":"Diabetes Metab Syndr"},{"issue":"4","key":"8103_CR36","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/idr13040080","volume":"13","author":"N Jahan","year":"2021","unstructured":"Jahan N, Rahman FI, Saha P, Ether SA, Roknuzzaman A, Sarker R, et al. Side effects following administration of the first dose of Oxford-AstraZeneca\u2019s Covishield vaccine in Bangladesh: a cross-sectional study. Infect Dis Rep. 2021;13(4):888\u2013901.","journal-title":"Infect Dis Rep"},{"issue":"2","key":"8103_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijwd.2021.01.007","volume":"7","author":"SM Rice","year":"2021","unstructured":"Rice SM, Ferree SD, Mesinkovska NA, Kourosh AS. The art of prevention: COVID-19 vaccine preparedness for the dermatologist. Int J Womens Dermatol. 2021;7(2):209\u201312.","journal-title":"Int J Womens Dermatol"},{"issue":"7","key":"8103_CR38","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3390\/jcm10071428","volume":"10","author":"A Riad","year":"2021","unstructured":"Riad A, Pokorn\u00e1 A, Attia S, Klugarov\u00e1 J, Ko\u0161\u010d\u00edk M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428.","journal-title":"J Clin Med"},{"issue":"10240","key":"8103_CR39","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845\u201354.","journal-title":"Lancet"},{"issue":"7","key":"8103_CR40","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.vaccine.2022.01.013","volume":"40","author":"L Rolfes","year":"2022","unstructured":"Rolfes L, H\u00e4rmark L, Kant A, van Balveren L, Hilgersom W, van Hunsel F. COVID-19 vaccine reactogenicity\u2014a cohort event monitoring study in the Netherlands using patient reported outcomes. Vaccine. 2022;40(7):970\u20136.","journal-title":"Vaccine"},{"issue":"12","key":"8103_CR41","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1002\/jmv.27214","volume":"93","author":"QA Al Khames Aga","year":"2021","unstructured":"Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of COVID-19 vaccines. J Med Virol. 2021;93(12):6588\u201394.","journal-title":"J Med Virol"},{"key":"8103_CR42","first-page":"1","volume":"18","author":"H Omeish","year":"2021","unstructured":"Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccines Immunother. 2021;18:1\u20138.","journal-title":"Hum Vaccines Immunother"},{"key":"8103_CR43","first-page":"98","volume":"379","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens S, Madhi S. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;379:98.","journal-title":"Lancet"},{"issue":"1","key":"8103_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how\u2019s and what\u2019s of vaccine reactogenicity. npj Vaccines. 2019;4(1):1\u201311.","journal-title":"npj Vaccines"},{"issue":"3","key":"8103_CR45","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/vaccines10030366","volume":"10","author":"MM Hatmal","year":"2022","unstructured":"Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Mohamud R, Fawaz M, Kateeb ET, et al. Reported adverse effects and attitudes among Arab populations following COVID-19 vaccination: a large-scale multinational study implementing machine learning tools in predicting post-vaccination adverse effects based on predisposing factors. Vaccines (Basel). 2022;10(3):366.","journal-title":"Vaccines (Basel)"},{"key":"8103_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.760047","volume":"8","author":"AN Alghamdi","year":"2021","unstructured":"Alghamdi AN, Alotaibi MI, Alqahtani AS, Al Aboud D, Abdel-Moneim AS. BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees. Front Med (Lausanne). 2021;8: 760047.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"8103_CR47","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/medicina58121799","volume":"58","author":"TH Mallhi","year":"2022","unstructured":"Mallhi TH, Khan YH, Butt MH, Salman M, Tanveer N, Alotaibi NH, et al. Surveillance of side effects after two doses of COVID-19 vaccines among patients with comorbid conditions: a sub-cohort analysis from Saudi Arabia. Medicina (Kaunas). 2022;58(12):1799.","journal-title":"Medicina (Kaunas)"},{"issue":"19","key":"8103_CR48","first-page":"5942","volume":"25","author":"MG Garc\u00eda-Araiza","year":"2021","unstructured":"Garc\u00eda-Araiza MG, Martinez-Cuazitl A, Cid-Dominguez BE, Uribe-Nieto R, Ortega-Portillo R, Almeyda-Farf\u00e1n JA, et al. Side effects of the BNT162b2 vaccine in the personnel of the Military Central Hospital. Eur Rev Med Pharmacol Sci. 2021;25(19):5942\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"8103_CR49","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2666-5247(21)00275-5","volume":"3","author":"A Angyal","year":"2022","unstructured":"Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe. 2022;3(1):e21\u201331.","journal-title":"Lancet Microbe"},{"key":"8103_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103401","volume":"68","author":"M Frieman","year":"2021","unstructured":"Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M, et al. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine. 2021;68: 103401.","journal-title":"EBioMedicine"},{"issue":"28","key":"8103_CR51","first-page":"2100634","volume":"26","author":"AA Powell","year":"2021","unstructured":"Powell AA, Power L, Westrop S, McOwat K, Campbell H, Simmons R, et al. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March\u2013June 2021, England. Euro Surveill Bull = Europeen sur les maladies transmissibles European communicable disease bulletin. 2021;26(28):2100634.","journal-title":"Euro Surveill Bull = Europeen sur les maladies transmissibles European communicable disease bulletin"},{"issue":"3","key":"8103_CR52","first-page":"249","volume":"11","author":"AG Mathioudakis","year":"2021","unstructured":"Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life (Basel, Switzerland). 2021;11(3):249.","journal-title":"Life (Basel, Switzerland)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08103-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08103-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08103-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:22:02Z","timestamp":1679862122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08103-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8103"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08103-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Shahroud University of Medical Sciences, Shahroud, Iran with the reference number of IR.SHMU.REC.1400.012. Participation in this study was entirely voluntary, and after explaining the study objectives and methods, a written consent form was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}